Impact of biological therapies on laboratory outcomes and FEV1 in patients with severe eosinophilic asthma with chronic rhinosinusitis: a real-life study from Saudi Arabia

• Published in: Multidisciplinary respiratory medicine 2024-09, Vol.19 (Vol. 19 (2024))
• Main Authors: Abu Elhassan, Usama, Al-Mani, Salihah Y, Alqahtani, Saad M A, Elnamaky, Medhat, Alfaifi, Abdulaziz, Alshehri, Mohammed A, Alasiri, Haneen A, Kadasah, Ali S, Musleh, Abdullah, Alshafa, Fawwaz A, Qureshi, Muhammad S S, Assiri, Abdulmohsen Y, Falqi, Abdulrahman I, Asiri, Bader I, Ahmed, Haider M O, Alshehry, Saleem, Abdalla, Abdelrahman M
• Format: Article
• Language: English
• ISSN: 1828-695X; 2049-6958
• DOI: 10.5826/mrm.2024.985

                                                                 Abstract Background: Few studies have addressed the effects of biological therapies on laboratory outcomes and changes in FEV1 in patients with severe asthma (SA) and chronic rhinosinusitis (CRS). We aimed to study the effect of three biological therapies on laboratory outcomes and FEV1 in Saudi Arabian patients with SA and CRS. From March to September 2022, a retrospective observational cohort study was undertaken at the severe asthma clinics of the Armed Forces Hospital-Southern Region (AFHSR) and King Khalid University Hospital, Abha, Saudi Arabia, to delineate the effects of 3 biological therapies (benralizumab, dupilumab, and omalizumab) in adults with SA and concomitant CRS in terms of FEV1 and laboratory parameters (serum IgE and eosinophilic counts). Eighty patients were enrolled, with a mean age of 46.68. There were 45 (56%) females and 35 (44%) males. There were significant improvements in FEV1 and laboratory parameters (serum IgE and eosinophilic counts) after 6 &12 months of biological therapies compared to pre-biological therapies (p